$786.19 Million in Sales Expected for Illumina (ILMN) This Quarter

Wall Street analysts predict that Illumina (NASDAQ:ILMN) will post sales of $786.19 million for the current fiscal quarter, according to Zacks. Seven analysts have issued estimates for Illumina’s earnings. The highest sales estimate is $796.93 million and the lowest is $775.00 million. Illumina posted sales of $662.00 million in the same quarter last year, which suggests a positive year-over-year growth rate of 18.8%. The business is scheduled to report its next quarterly earnings results on Tuesday, August 7th.

According to Zacks, analysts expect that Illumina will report full year sales of $3.20 billion for the current financial year, with estimates ranging from $3.17 billion to $3.25 billion. For the next fiscal year, analysts forecast that the company will post sales of $3.57 billion per share, with estimates ranging from $3.45 billion to $3.78 billion. Zacks’ sales averages are an average based on a survey of sell-side analysts that that provide coverage for Illumina.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Tuesday, April 24th. The life sciences company reported $1.45 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.02 by $0.43. Illumina had a return on equity of 24.93% and a net margin of 19.31%. The company had revenue of $782.00 million during the quarter, compared to analyst estimates of $744.30 million. During the same quarter last year, the business posted $0.64 earnings per share. The firm’s revenue was up 30.8% on a year-over-year basis.

Several research analysts have issued reports on ILMN shares. BidaskClub upgraded Illumina from a “buy” rating to a “strong-buy” rating in a research report on Thursday, April 19th. Morgan Stanley boosted their target price on Illumina from $170.00 to $180.00 and gave the company an “underweight” rating in a research report on Wednesday, April 25th. Citigroup upgraded Illumina from a “neutral” rating to a “buy” rating and boosted their target price for the company from $260.00 to $275.00 in a research report on Monday, February 5th. Barclays upgraded Illumina from an “equal weight” rating to an “overweight” rating and set a $235.00 target price for the company in a research report on Monday, May 7th. Finally, Zacks Investment Research upgraded Illumina from a “hold” rating to a “buy” rating and set a $270.00 target price for the company in a research report on Monday, April 16th. One analyst has rated the stock with a sell rating, five have given a hold rating, fifteen have issued a buy rating and two have given a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $253.36.

Shares of Illumina opened at $272.44 on Friday, MarketBeat.com reports. Illumina has a 1 year low of $167.98 and a 1 year high of $275.34. The company has a market cap of $39.15 billion, a price-to-earnings ratio of 68.11, a price-to-earnings-growth ratio of 2.85 and a beta of 0.86. The company has a quick ratio of 2.41, a current ratio of 2.71 and a debt-to-equity ratio of 0.23.

In other news, EVP Omead Ostadan sold 1,314 shares of Illumina stock in a transaction that occurred on Wednesday, May 2nd. The shares were sold at an average price of $242.60, for a total transaction of $318,776.40. Following the completion of the sale, the executive vice president now owns 27,153 shares of the company’s stock, valued at $6,587,317.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Charles Dadswell sold 116 shares of Illumina stock in a transaction that occurred on Tuesday, April 3rd. The shares were sold at an average price of $230.91, for a total transaction of $26,785.56. Following the sale, the senior vice president now directly owns 7,875 shares of the company’s stock, valued at approximately $1,818,416.25. The disclosure for this sale can be found here. Insiders have sold 26,035 shares of company stock valued at $6,611,597 in the last ninety days. Insiders own 0.54% of the company’s stock.

Several institutional investors have recently bought and sold shares of ILMN. Schwab Charles Investment Management Inc. raised its stake in Illumina by 6.4% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 541,063 shares of the life sciences company’s stock worth $118,217,000 after buying an additional 32,695 shares in the last quarter. Robeco Institutional Asset Management B.V. raised its stake in Illumina by 258.8% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 8,045 shares of the life sciences company’s stock worth $1,758,000 after buying an additional 5,803 shares in the last quarter. LMR Partners LLP raised its stake in Illumina by 101.5% in the fourth quarter. LMR Partners LLP now owns 5,849 shares of the life sciences company’s stock worth $1,278,000 after buying an additional 2,946 shares in the last quarter. Mutual of America Capital Management LLC raised its stake in Illumina by 8.6% in the fourth quarter. Mutual of America Capital Management LLC now owns 18,752 shares of the life sciences company’s stock worth $4,097,000 after buying an additional 1,492 shares in the last quarter. Finally, Northwestern Mutual Wealth Management Co. raised its stake in Illumina by 38.9% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 993 shares of the life sciences company’s stock worth $217,000 after buying an additional 278 shares in the last quarter. 90.75% of the stock is owned by hedge funds and other institutional investors.

About Illumina

Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.

Get a free copy of the Zacks research report on Illumina (ILMN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply